Juno Therapeutics, a company which specialises in cellular cancer immunotherapies, especially chimeric antigen receptors (CARs) and T-cell receptors (TCRs), expands its portfolio to small molecule modulators with its acquisition of RedoxTherapies. Juno will pay US$10 M upfront, with the potential for milestone payments, which will allow Juno to investigate combination therapies, giving it an advantage over other CAR-T developers.